{"name":"ImmuneOncia Therapeutics Inc.","slug":"immuneoncia-therapeutics-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMirgFBVV95cUxORk5zdWNrQTFzcUhGcGNwS3lwMXZIUGVwUEo5UFctQ3FmUnRyUm1mLURMSHJTb25xWWlIV0lsdmlhemdCM0p5RzZUdUc4R21sSlRlX3VURzhMNkpCQWJySmk0VWk5dThOS3FLY3J5ZEw4dzIycHZXOVFuYVlSSjJpNlI5OHRoSDdtYjlIUV9UNHRzVG1hZTJOazZ4eFdmNzM4TDhBcmVpaXBZcTNiMXc?oc=5","date":"2026-04-08","type":"pipeline","source":"Drug Discovery News","summary":"ImmuneOncia signs manufacturing agreement with Lonza for Danburstotug - Drug Discovery News","headline":"ImmuneOncia signs manufacturing agreement with Lonza for Danburstotug","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinwFBVV95cUxPMzAtU1hYbmg3Y2VMWEhhYTNpWC16VmlvTWJnMDZPWG1HZmV2Y3hERjVaUlJJMjFxVVk5Y3M4R3NWUEc5UDBXSjVEM25GQ21yMXhSYkhpQXlDY091ZWtJU1hZS0tvSjZHcHFtU1pYYm1UZ09WbmVlUG1VYXRxaEg3RXE0VmFTYmotMDI0OGdzbXA4SE0tZl9DMmRtVmJYd1k?oc=5","date":"2026-04-05","type":"trial","source":"marketscreener.com","summary":"ImmuneOncia Therapeutics, Inc.: Dividend historical data and projections - marketscreener.com","headline":"ImmuneOncia Therapeutics, Inc.: Dividend historical data and projections","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixgFBVV95cUxPbW0yVGRSUGFXeE9kR3F2cWNIMnBsM2NlZDdib0RtN0RMblpZWnQxd19wMEU5Ym90UjBCZzhnQzlna3hDdkh5TDFIa29ncEpSS1k2QUZGeG81Sm1odG1BanIybVZEc3hmVm5TeXdxWEV4S3BkdUlTTXM4YmtOYUY5QkYtazlHUkh5eTlDdmJONEFSWGRxUmdoMVY1NVVaSjZyTlJUUHlhSlE1blhIb0JXbzZub2hFNEZvRDVWOTdhLTd3Y3RQUWc?oc=5","date":"2026-03-30","type":"pipeline","source":"Contract Pharma","summary":"ImmuneOncia, Lonza Sign Manufacturing Pact for Late‑Stage Antibody Program - Contract Pharma","headline":"ImmuneOncia, Lonza Sign Manufacturing Pact for Late‑Stage Antibody Program","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTFBVdmpjR0hXVFh4MFBUdlNQYXlVeEZMRmVXSmlwaXdFSlJPRkJRRVNzYnBSb1VST3JQS2NpWE95NFVjX3BXdmpBNlE1Q2o1VmFmU2J6dGJUZ2lIN01lajh1R0cwSFNLQVlDZG1wbjJ30gFyQVVfeXFMTldlelBNR2VGVndnSW12MDJ2MkR6dnk5SkN1YUo4VUsxMjRpdVBnQkhNU0lwUExPR1ZPcm0zRVZVSHVjeTNtNXhHZDBYRFZzT1lWVjBLQnlRX2ZSNC1KM2RqYVpaWDFoMTBadjFWQ3dlaTlR?oc=5","date":"2026-02-24","type":"pipeline","source":"koreabiomed.com","summary":"ImmuneOncia bets $83 million on rare cancer breakthrough - koreabiomed.com","headline":"ImmuneOncia bets $83 million on rare cancer breakthrough","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigAFBVV95cUxQbjhTTUdwS2lvZDIxWGE5cmdjN18ycUxpSDZjSng3OTE0cGRySFZQWUs4M1JPdG9fWURscjVHVXZaRlpMTk5tR2pLVlNPam52bGVlcWgwN3FSZjlUaV9QVGxxNXFYSUlmZjl5V0VmeDNmWmhnOUZSVGZlc2NQLTlCQtIBlAFBVV95cUxNZFFzVTMtaHFHcjBvY0s1dWh4dDNfUlp4WlpWaU5XOVhndkF0X0FPRVRpSVREbXZnS3RUdWpDUE91UVE0a0ZPYVhuOXV0M0h5T2NNVG1XRzIxX2RoOTM1MVA5elNHNmFOcm5ERnZMVlZOUUFUU0YyVkFxd0MtdHYxTXdlV1N6NWdidmc5akdOekZsLVNP?oc=5","date":"2026-02-10","type":"pipeline","source":"Chosunbiz","summary":"Yuhan hesitation over ImmuneOncia rights offering fuels Korea biotech backlash - CHOSUNBIZ - Chosunbiz","headline":"Yuhan hesitation over ImmuneOncia rights offering fuels Korea biotech backlash - CHOSUNBIZ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTFBhczU4NDRUUGJQcXRiYXpLTTk0WHdkUFJFTHhYNnVxbGctVEhkQlV2SXFQLXdtNF80SzNfVUg3YXdjNERGcmJqX3hmWVNOZk1GYUxOVXg1dWVkdXZPZS1RR2J2dXU4RXlHeG9uRzdB0gFyQVVfeXFMUENYRWVDZWoxSlFCeFpJTTA0RGpoNzhObVZVQkI5bzVuOFVobS1PSFBvYnpPSUlaMWJXNUI5bFRqelNRbGh6VFRQMDhGWHluUWRYalYzSnlmSkdQV2lNSUNHZGd3NkUzVHAyT0NzNWtpUlhR?oc=5","date":"2025-12-05","type":"pipeline","source":"koreabiomed.com","summary":"ImmuneOncia reports 63% complete response with Danburstotug in NK/T-cell lymphoma - koreabiomed.com","headline":"ImmuneOncia reports 63% complete response with Danburstotug in NK/T-cell lymphoma","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinwFBVV95cUxQejVOQWEzZlFvQV9sYlB3ZkpsbC1MdVk2aDBLa2gxOVF2S3RiT0dHUURIOWc3VVUzWGgyNHVOUVFfVW5WYmdiNlYtdVp0M2k3M25Rb2JldERDQTZnVGhiSUZveDlGOGRRdVB4cHhIRWNwXzRtU0YyeHlZWW5YeHB3WjBwWVhBY1pWT09oek1heGhzNnVuMHVibGl6Vy03YUk?oc=5","date":"2025-09-09","type":"pipeline","source":"BioWorld News","summary":"Biopharma IPO activity slows, but 2025 returns are surging - BioWorld News","headline":"Biopharma IPO activity slows, but 2025 returns are surging","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilgFBVV95cUxPSEtPaGNTbVhBZmxzc3BsNGdIX2hMUkZMdGRubmxEUy1PVVJnVENKcGxkdUlhQnV3S0ZndTE0c1dtMWk3MUhVOVlQaEZSc2MwOW1iVUFLWkpYelQ4bDFTSlB1UUh3U1I2cFQ5MlE5clBDZ1Fsa2NJcWIydjJVVkZmdkVtaWF3SXVjVmx2dGdvWW5ubF9kTnc?oc=5","date":"2025-06-17","type":"pipeline","source":"Manufacturing Chemist","summary":"Veranova announces cGMP bioconjugation expansion in Devens - Manufacturing Chemist","headline":"Veranova announces cGMP bioconjugation expansion in Devens","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihgFBVV95cUxNRkotRUpNQzY0dERhU05hSG1FRU5fX1RFYWY3MVZQaXNyYjg2dEUwMGtTeWY3c01xeVJiTGlrS0NIUElIeHRORkRSMkpXbm84V0lzMENBMjlFNWNvMUs4M2FjdzBjQkw1NGlPdDNBQXR3b0haak0zNFMybE1HNlFmUkJmVkZxQQ?oc=5","date":"2025-05-02","type":"pipeline","source":"BioWorld News","summary":"Three Korea biotechs prep for May IPOs - BioWorld News","headline":"Three Korea biotechs prep for May IPOs","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxPQkxNMHp0d3NQR2RQb2lZcjF2RV9NOE9NMkhKNmhrbmE0Y2lJd09UYUQ2NnhGMHpya1pST3JoY3FnNzd6b2NySlpGMy0wWEVwWnpJN1JvZEQxRDhpQ0N2SWFhcmlRU0o2Q1c1V2d6c0lIYWRZNVUxQjNDSEhDd2hOaG5mV01JX3RxMTJrOEd6REZwUVNSNUpIaFd2MUdUVGNRRUJPYWcwTTlaYkR2cWZxSGMwTzZGaTND?oc=5","date":"2024-06-03","type":"trial","source":"BioSpace","summary":"ImmuneOncia Announces Biomarker Results from Phase 1 Clinical Trial of CD47 Antibody at ASCO - BioSpace","headline":"ImmuneOncia Announces Biomarker Results from Phase 1 Clinical Trial of CD47 Antibody at ASCO","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE5PWjlPZGVmYXJQdWVuVDZDUE55bHNERzdCQXJIa0xBckZzMFRfZVA4cm5EcW56U3dOUmtLLTNmakFxSDV6cUNjTm44cW0xNzBsSC02Y0o1cHpLVURVTVdZ?oc=5","date":"2020-09-01","type":"pipeline","source":"Nature","summary":"Novel immunotherapies to combine with PD-1/PD-L1 treatment - Nature","headline":"Novel immunotherapies to combine with PD-1/PD-L1 treatment","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1wFBVV95cUxQRzV0RkV0Sk4zN19JR3Q1Z2V6aEZNVVZ5WWxPcVZsRDIzbkVQbTRpa09aN1lPdFBWN1BzczlueXE5Zmx5MTdtY2gyUHJSd05vOTlibEVTQlhqbTh0OHc5V0NsRVRXdG50TjNyc1FIMjllTWdHTkNuY3BIcHVPSjZqc3NFM1pJaHBsV040Rl9pN2llMEFLcFc3UkFlcHR4NU9QbG5LdHhjcDVYTzVTQU1KRGw4clRzSnFQazhiR19OLVpJV0Jwa2dFdzNUaE1zR0lNYThQZTd3bw?oc=5","date":"2016-03-02","type":"pipeline","source":"PR Newswire","summary":"Yuhan Corporation And Sorrento Therapeutics Form Joint Venture Company - ImmuneOncia - PR Newswire","headline":"Yuhan Corporation And Sorrento Therapeutics Form Joint Venture Company - ImmuneOncia","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":2,"visitCount":3,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}